Beam Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will participate in a panel at the 2022 Wedbush PacGrow Virtual Healthcare Conference on August 9, 2022, at 9:45 a.m. ET. The panel is titled "So Let it Be (Re)Written - Updates in Gene Modulation." Interested parties can access a live webcast on the investor section of Beam's website, which will be archived for 60 days post-event. Beam is focused on precision genetic medicines, utilizing proprietary base editing technology to advance its therapeutic programs.
- None.
- None.
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a panel titled, “So Let it Be (Re)Written - Updates in Gene Modulation” during the 2022 Wedbush PacGrow Virtual Healthcare Conference on Tuesday, August 9, 2022 at 9:45 a.m. ET.
A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Beam Therapeutics' conference participation?
Where can I watch the Beam Therapeutics conference presentation?
What is Beam Therapeutics' focus in biotechnology?
Who is speaking at the Wedbush conference for Beam Therapeutics?
What is the significance of base editing in Beam Therapeutics' work?
